Zealand Pharma A/S (ZLDPF)
| Market Cap | 2.50B -51.6% |
| Revenue (ttm) | 709.63M -49.0% |
| Net Income | 418.86M -59.0% |
| EPS | 5.79 -58.9% |
| Shares Out | n/a |
| PE Ratio | 6.36 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 36.77 |
| Previous Close | 34.60 |
| Day's Range | 36.77 - 37.00 |
| 52-Week Range | 33.08 - 83.12 |
| Beta | 0.61 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]
News
Boehringer, Zealand's obesity drug did not raise heart risks in trial, data shows
Zealand Pharma and Boehringer Ingelheim's experimental obesity drug did not increase the risk of serious heart problems compared to a placebo in a late-stage trial, the companies said on Monday.
Zealand Pharma says Boehringer Ingelheim Phase 3 trial met primary endpoint
Zealand Pharma (ZLDPF) announced that Boehringer Ingelheim has reported results from the Phase 3 SYNCHRONIZE-CVOT trial, the first and only global cardiovascular safety trial of a glucagon/GLP-1 dual ...
Zealand Pharma's ZP9830 Shows Favorable Tolerability In Phase 1 Trial
(RTTNews) - Monday, Zealand Pharma A/S (ZEAL.CO) announced positive topline results from the multiple ascending dose (MAD) portion of its Phase 1 trial evaluating ZP9830, an investigational Kv1.3 ion ...
Zealand Pharma announces results from ZP9830 trial
Zealand Pharma (ZLDPF) announced Phase 1 multiple ascending dose, or MAD, topline results for the company’s Kv1.3 ion channel blocker, ZP9830. The MAD part of the first-in-human, single-center, random...
Zealand And Generate Biomedicines Team Up To Develop AI-Designed Therapies For Metabolic Diseases
(RTTNews) - Artificial intelligence is playing an increasingly important role in drug development, and Zealand Pharma (ZEAL) and Generate Biomedicines are the latest companies to combine their experti...
Zealand Pharma, Generate Biomedicines Partner To Develop AI-Designed Metabolic Disease Therapies
(RTTNews) - Zealand Pharma A/S (ZEAL.CO), a biotechnology company, announced a multi-target strategic collaboration with Generate Biomedicines Inc. (GENB) to design and develop multispecific protein t...
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion
Zealand Pharma and Generate Biomedicines said on Tuesday they have partnered to develop protein-based treatments for obesity and other metabolic diseases using AI, in a deal worth up to nearly $1.2 bi...
Generate Biomedicines, Zealand Pharma enter protein therapeutics pact
Generate Biomedicines (GENB) announced a multi-target strategic collaboration with Zealand Pharma (ZLDPF). Under the collaboration, the companies intend to design and develop multispecific protein the...
Zealand Pharma opens research hub in Cambridge, Massachusetts
Zealand Pharma (ZLDPF) celebrated the opening of its new research hub at 35 CambridgePark Drive in Cambridge, Massachusetts, with a ribbon-cutting ceremony. The site, first announced in March 2026, is...
Zealand Pharma slides as concerns over patients quitting survodutide trials resurface
Nearly one in five patients quit Zealand Pharma's late-stage survodutide trial due to gastrointestinal side effects caused by the obesity drug, data released on Thursday showed, again raising invest...
Zealand announces initiation of registrational Phase 3 ZUPREME program
Zealand Pharma (ZLDPF) announces the initiation of the global registrational Phase 3 ZUPREME program, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with overw...
Zealand Pharma's short bowel syndrome drug wins backing from EU panel
Zealand Pharma received a positive opinion from the Committee for Medicinal Products for Human Use recommending approval of its drug candidate Zeydovio for the treatment of short bowel syndrome, the...
Zealand Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted ambitious growth plans in metabolic health, with a focus on launching petrelintide and advancing combination therapies for obesity, supported by strong partnerships with Roche and Boehringer. Key rare disease assets and an expanding early-stage pipeline underscore a strategy centered on innovation, patient-centricity, and upcoming pivotal data and regulatory milestones.
Elvinix announces exclusive license agreement with Zealand Pharma
Elvinix announced an exclusive license agreement with Zealand Pharma (ZLDPF), granting Elvinix the rights to develop and commercialize Zealand’s GLP-1/gastrin dual-agonist peptide portfolio. Under the...
Zealand Pharma downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Zealand Pharma (ZLDPF) to Equal Weight from Overweight with a price target of DKK 330, down from DKK 425. The company has a “lean slate” of potential catalysts…
Zealand Pharma price target lowered to DKK 435 from DKK 460 at JPMorgan
JPMorgan lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 435 from DKK 460 and keeps an Overweight rating on the shares.
Zealand Pharma enters $100M royalty purchase, sale pact with Royalty Pharma
Zealand Pharma (ZLDPF) announced that it has entered into a royalty purchase and sale agreement with Royalty Pharma (RPRX) in exchange for Zealand Pharma’s economics related to rusfertide, a potential...
Zealand Pharma price target raised to DKK 420 from DKK 410 at Wells Fargo
Wells Fargo raised the firm’s price target on Zealand Pharma (ZLDPF) to DKK 420 from DKK 410 and keeps an Overweight rating on the shares. The company reported inline Q2…
Zealand Pharma Earnings Call Transcript: Q2 2026
Strong H1 2026 performance with double-digit weight loss from petrelintide, robust cash position, and key pipeline advances. Survodutide phase III trials met endpoints, and $100M royalty monetization boosts capital for strategic growth.
Zealand Pharma Quarterly report: Q2 2026
Zealand Pharma has published its Q2 2026 quarterly earnings report on August 13, 2026.
Zealand Pharma Slides: Q2 2026
Zealand Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Zealand Pharma downgraded to Hold from Buy at Jefferies
Jefferies downgraded Zealand Pharma (ZLDPF) to Hold from Buy with a price target of DKK 320, down from DKK 505. The firm is citing the absence of key value-crystallizing catalysts…
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on...
Zealand Pharma downgraded to Hold from Buy at Berenberg
Berenberg downgraded Zealand Pharma (ZLDPF) to Hold from Buy with a price target of DKK 300, down from DKK 825. The firm believes it will take longer than anticipated to…
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am...